HR-10127-119
Referred to the House Committee on Energy and Commerce.
Sponsored by Nancy Mace (R-SC)
What it does
This bill would prohibit any federal funds from being used, directly or indirectly, to conduct, support, or fund research studying the effects of gender-related medical treatments, including hormone therapy, puberty blockers, and related surgical procedures. The prohibition applies regardless of other existing laws and covers research examining these treatments in both people identified as female and male seeking to change sex characteristics.
Who benefits
Advocacy groups and lawmakers who oppose gender-related medical treatments for minors or adults may see this as achieving a policy goal without needing to regulate the treatments directly. Researchers in other fields could see redirected funding if agency budgets are reallocated.
Who is hurt
Medical researchers and academic institutions (e.g., NIH-funded universities) studying outcomes, risks, and benefits of gender-related medical treatments would lose funding sources. Transgender and gender-nonconforming individuals and their physicians would lose access to future federally funded studies on treatment safety and efficacy, potentially leaving both supporters and critics of these treatments with less data to inform clinical guidelines and policy. Patients seeking evidence-based care, insurers evaluating coverage decisions, and public health officials relying on federally funded data would also be affected by the resulting research gap.
Supporters argue
Supporters argue that federal research dollars should not be spent studying medical interventions they consider experimental or harmful, particularly for minors, and that halting funding removes what they see as an implicit government endorsement of these treatments. They contend that existing research in this area is contested and that Congress, as the appropriator of federal funds, has the authority to direct how those funds are used regardless of the underlying medical debate.
Opponents argue
Opponents argue that cutting off research funding would not stop these treatments from being provided but would eliminate the data needed to evaluate their safety and effectiveness, harming patients, clinicians, and policymakers on all sides of the debate. They contend that singling out one category of medical treatment for a research ban, defined broadly enough to include hormone therapy and numerous surgical procedures, sets a precedent for politically motivated restrictions on scientific inquiry more broadly.
Constitutional context
Congress has broad authority under the Spending Clause (Art. I, §8, cl. 1) to condition or withhold federal funds, including for research, and courts have generally given Congress wide latitude to decide what activities federal money may support. There is no individual right to federally funded research, so this bill raises fewer direct constitutional questions than treatment mandates or bans themselves, though critics may raise First Amendment academic freedom arguments that courts have historically viewed skeptically when the government simply declines to fund speech or research.
Checks and balances
Congress would exercise its spending power to restrict executive agencies (such as NIH and HHS) from funding a category of research, limiting agency discretion in grantmaking with no built-in review mechanism beyond future appropriations changes.
Historical precedent
Congress has previously restricted federal research funding in politically contested areas, such as the Dickey Amendment's long-standing limits on federal funding for gun violence research and past restrictions on federal funding for certain embryonic stem cell research.